Diagnosis and Anticoagulant Treatment

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 2, 2013, Pages 187-198

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; HUMAN; LUNG EMBOLISM; PRACTICE GUIDELINE; VEIN THROMBOSIS; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 84893416638     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612474840n     Document Type: Article

References (163)

1. Zierler BK. Ultrasonography and diagnosis of venous thromboembolism. Circulation. 2004; 109(12 suppl 1):I9-I14.
2. Kearon C Julian JA Newman TE Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative. Ann Intern Med. 1998; 128(8):663-677.
3. Cogo A Lensing AW Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ. 1998; 316(7124):17-20.
4. Birdwell BG Raskob GE Whitsett TL, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998; 128(1):1-7.
5. Robertson PL Goergen SK Waugh JR Fabiny RP. Colour-assisted compression ultrasound in the diagnosis of calf deep venous thrombosis. Med J Aust. 1995; 163(10):515-518.
6. Robertson PL Berlangieri SU Goergen SK, et al. Comparison of ultrasound and blood pool scintigraphy in the diagnosis of lower limb deep venous thrombosis. Clin Radiol. 1994; 49(6):382-390.
7. Rose SC Zwiebel WJ Nelson BD, et al. Symptomatic lower extremity deep venous thrombosis: accuracy, limitations, and role of color duplex flow imaging in diagnosis. Radiology. 1990; 175(3):639-644.
8. Rosier H Bellin MF Bousquet JC Radier C Lang T Grellet J. Prospective study of echography versus phlebography in the detection of sural venous thrombosis. J Radiol. 1992; 73(11):579-584.
9. Savy-Stortz C Nove-Josserand R Dubost A Durand DV Levrat R. Venous ultrasonography coupled with continuous Doppler in the diagnosis of deep venous thrombosis of the lower limbs. Evaluation in symptomatic patients. Presse Med. 1995; 24(7):341-344.
10. Simons GR Skibo LK Polak JF Creager MA Klapec-Fay JM Goldhaber SZ. Utility of leg ultrasonography in suspected symptomatic isolated calf deep venous thrombosis. Am J Med. 1995; 99(1):43-47.
11. Wells PS Anderson DR Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997; 350(9094):1795-1798.
12. Wells PS Anderson DR Bormanis J, et al. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis. Thromb Haemost. 1999; 81(4):493-497.
13. Wells PS Owen C Doucette S Fergusson D Tran H. Does this patient have deep vein thrombosis? JAMA. 2006; 295(2):199-207.
14. Kahn SR Joseph L Abenhaim L Leclerc JR. Clinical prediction of deep vein thrombosis in patients with leg symptoms. Thromb Haemost. 1999; 81(3):353-357.
15. Constans J Boutinet C Salmi LR, et al. Comparison of four clinical prediction scores for the diagnosis of lower limb deep venous thrombosis in outpatients. Am J Med. 2003; 115(6):436-440.
16. Buller HR Ten Cate-Hoek AJ Hoes AW, et al. Safely ruling out deep venous thrombosis in primary care. Ann Intern Med. 2009; 150(4):229-235.
17. Wells PS Anderson DR Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003; 349(13):1227-1235.
18. Johnson SA Stevens SM Woller SC, et al. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA. 2010; 303(5):438-445.
19. Sevestre MA Labarere J Casez P, et al. Accuracy of complete compression ultrasound in ruling out suspected deep venous thrombosis in the ambulatory setting. A prospective cohort study. Thromb Haemost. 2009; 102(1):166-172.
20. Stevens SM Elliott CG Chan KJ Egger MJ Ahmed KM. Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. Ann Intern Med. 2004; 140(12):985-991.
21. Schoepf UJ Kucher N Kipfmueller F Quiroz R Costello P Goldhaber SZ. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 2004; 110(20):3276-3280.
22. Wells PS Anderson DR Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 2001; 135(2):98-107.
23. Gibson NS Sohne M Kruip MJ, et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost. 2008; 99(1):229-234.
24. Klok FA Mos IC Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med. 2008; 168(19):2131-2136.
25. Douma RA Mos IC Erkens PM, et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med. 2011; 154(11):709-718.
26. Douma RA le Gal G Sohne M, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ. 2010; 340: c1475.
27. van Es J Mos I Douma R, et al. The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off increases the number of patients in whom acute pulmonary embolism can safely be excluded. Thromb Haemost. 2012; 107(1):167-171.
28. Rathbun SW Raskob GE Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. 2000; 132(3):227-232.
29. O'Neill J Murchison JT Wright L Williams J. Effect of the introduction of helical CT on radiation dose in the investigation of pulmonary embolism. Br J Radiol. 2005; 78(925):46-50.
30. Stein PD Matta F. Acute pulmonary embolism. Curr Probl Cardiol. 2010; 35(7):314-376.
31. Carrier M Righini M Wells PS, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost. 2010; 8(8):1716-1722.
32. Buller HR Agnelli G Hull RD Hyers TM Prins MH Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(suppl 3):401S-428S.
33. Wille-Jorgensen P Jorgensen LN Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis. Thromb Haemost. 2005; 93(2):236-241.
34. Schindler OS Dalziel R. Post-thrombotic syndrome after total hip or knee arthroplasty: incidence in patients with asymptomatic deep venous thrombosis. J Orthop Surg (Hong Kong). 2005; 13(2):113-119.
35. Gillet JL Perrin MR Allaert FA. Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis. J Vasc Surg. 2007; 46(3):513-519.
36. Brandjes DP Heijboer H Buller HR de Rijk M Jagt H ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992; 327(21):1485-1489.
37. Albada J Nieuwenhuis HK Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation. 1989; 80(4):935-940.
38. Bratt G Aberg W Johansson M Tornebohm E Granqvist S Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost. 1990; 64(4):506-510.
39. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemost. 1991; 65(3):251-256.
40. Breddin HK Hach-Wunderle V Nakov R Kakkar VV. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med. 2001; 344(9):626-631.
41. Hull RD Raskob GE Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992; 326(15):975-982.
42. Prandoni P Lensing AW Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992; 339(8791):441-445.
43. Lopaciuk S Meissner AJ Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost. 1992; 68(1):14-18.
44. Simonneau G Charbonnier B Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med. 1993; 153(13):1541-1546.
45. Lindmarker P Holmstrom M Granqvist S Johnsson H Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994; 72(2):186-190.
46. Monreal M Lafoz E Olive A del Rio L Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994; 71(1):7-11.
47. Alhenc-Gelas M Jestin-Le Guernic C Vitoux JF Kher A Aiach M Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-study group. Thromb Haemost. 1994; 71(6):698-702.
48. Simonneau G Sors H Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE study group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. N Engl J Med. 1997; 337(10):663-669.
49. Findik S Erkan ML Selcuk MB Albayrak S Atici AG Doru F. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration. 2002; 69(5):440-444.
50. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus investigators. N Engl J Med. 1997; 337(10):657-662.
51. Hull RD Raskob GE Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992; 152(8):1589-1595.
52. Brill-Edwards P Ginsberg JS Johnston M Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993; 119(2):104-109.
53. Burotto M Gabrielli L Crossley N. Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
54. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Arch Intern Med. 2004;164:1077-1083.
55. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Rev Med Chil. 2004; 132(9):1140-1143.
56. Anand S Ginsberg JS Kearon C Gent M Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med. 1996; 156(15):1677-1681.
57. Anand SS Bates S Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med. 1999; 159(17):2029-2032.
58. Charbonnier BA Fiessinger JN Banga JD Wenzel E d'Azemar P Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. Thromb Haemost. 1998; 79(5):897-901.
59. Merli G Spiro TE Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001; 134(3):191-202.
60. Couturaud F Julian JA Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost. 2001; 86(4):980-984.
61. Harenberg J Riess H Buller HR Brom J Weidinger G Huisman MV. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin. Haematologica. 2003; 88(10):1157-1162.
62. Koopman MM Prandoni P Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman study group. N Engl J Med. 1996; 334(11):682-687.
63. Levine M Gent M Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996; 334(11):677-681.
64. Lapidus L Borretzen J Fahlen M, et al. Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients. Pathophysiol Haemost Thromb. 2002; 32(2):59-66.
65. Rodger MA Gagne-Rodger C Howley HE Carrier M Coyle D Wells PS. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy. Thromb Res. 2003; 112(1-2):13-18.
66. Segal JB Bolger DT Jenckes MW, et al. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med. 2003; 115(4):298-308.
67. Spyropoulos AC Hurley JS Ciesla GN de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest. 2002; 122(1):108-114.
68. Boccalon H Elias A Chale JJ Cadene A Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the vascular midi-pyrenees study. Arch Intern Med. 2000; 160(12):1769-1773.
69. Dunn AS Schechter C Gotlin A, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med. 2001; 110(6):458-462.
70. Schwarz T Schmidt B Hohlein U Beyer J Schroder HE Schellong SM. Eligibility for home treatment of deep vein thrombosis: prospective study. Br Med J. 2001; 322(7296):1212-1213.
71. Gallus A Jackaman J Tillett J Mills W Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986; 2(8519):1293-1296.
72. Hull RD Raskob GE Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990; 322(18):1260-1264.
73. Buller HR Davidson BL Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004; 140(11):867-873.
74. Buller HR Davidson BL Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003; 349(18):1695-1702.
75. Kearon C Gent M Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999; 340(12):901-907.
76. Schulman S Granqvist S Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The duration of anticoagulation trial study group. N Engl J Med. 1997; 336(6):393-398.
77. Kearon C Ginsberg JS Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349(7):631-639.
78. Hylek EM Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120(11):897-902.
79. Hull R Hirsh J Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982; 307(27):1676-1681.
80. Koo S Kucher N Nguyen PL Fanikos J Marks PW Goldhaber SZ. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med. 2004; 164(14):1557-1560.
81. Leroyer C Bressollette L Oger E, et al. Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX study group. Haemostasis. 1998; 28(2):70-77.
82. Ridker PM Goldhaber SZ Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 348(15):1425-1434.
83. Bauersachs R Berkowitz SD Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN investigators. N Engl J Med. 2010; 363(26):2499-2510.
84. Buller HR Prins MH Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2009; 366(14):1287-1297.
85. Buller H Deitchman D Prins M Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008; 6(8):1313-1318.
86. Schulman S Kearon C Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-2352.
87. Schulman S Baanstra D Eriksson H, et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism Abstract. Paper presented at ISTH, 2011; Kyoto.
88. Schulman S Eriksson H Goldhaber S, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism Abstract. Paper presented at: ISTH, 2011;,Kyoto.
89. Becattini C Agnelli G Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012; 366(21):1959-1967.
90. Hull RD Pineo GF Brant RF, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007; 120(1):72-82.
91. Hull RD Pineo GF Brant R, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009; 122(8):762-769 e3.
92. Lopez-Beret P Orgaz A Fontcuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001; 33(1):77-90.
93. Romera A Cairols MA Vila-Coll R, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 2009; 37(3):349-356.
94. Lopaciuk S Bielska-Falda H Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999; 81(1):26-31.
95. Lee AY Levine MN Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2):146-153.
96. Hull RD Pineo GF Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119(12):1062-1072.
97. Deitcher SR Kessler CM Merli G Rigas JR Lyons RM Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12(4):389-396.
98. Meyer G Marjanovic Z Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162(15):1729-1735.
99. Kearon C Akl EA Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141(suppl 2):e419S-e494S.
100. Das SK Cohen AT Edmondson RA Melissari E Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996; 20: 521-526.
101. Daskalopoulos ME Daskalopoulou SS Liapis CD. Tinzaparin in long-term treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 2007; 34(3):353-354.
102. Gonzalez-Fajardo JA Arreba E Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg. 1999; 30(2):283-292.
103. Kakkar VV Gebska M Kadziola Z Saba N Carrasco P. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost. 2003; 89(4):674-680.
104. Hull RD Liang J Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med. 2011; 124(8):756-765.
105. Daskalopoulos ME Daskalopoulou SS Tzortzis E, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg. 2005; 29(6):638-650.
106. Buller HR Cohen AT Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease The van Gogh investigators. N Engl J Med. 2007; 357(11):1094-1104.
107. Buller HR Gallus AS Pillion G Prins MH Raskob GE. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012; 379(9811):123-129.
108. Prandoni P Lensing AW Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125(1):1-7.
109. Levine MN Hirsh J Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995; 74(2):606-611.
110. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research committee of the British thoracic society. Lancet. 1992; 340(8824):873-876.
111. Baglin T Luddington R Brown K Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003; 362(9383):523-526.
112. Christiansen SC Cannegieter SC Koster T Vandenbroucke JP Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005; 293(19):2352-2361.
113. Hansson PO Sorbo J Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000; 160(6):769-774.
114. Heit JA Mohr DN Silverstein MD Petterson TM O'Fallon WM Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000; 160(6):761-768.
115. Palareti G Legnani C Cosmi B Guazzaloca G Pancani C Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002; 87(1):7-12.
116. Pinede L Ninet J Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001; 103(20):2453-2460.
117. Pini M Aiello S Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost. 1994; 72(2):191-197.
118. Schulman S Rhedin AS Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of anticoagulation trial study group. N Engl J Med. 1995; 332(25):1661-1665.
119. Boutitie F Pinede L Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. Br Med J. 2011; 342: d3036.
120. Murin S Romano PS White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost. 2002; 88(3):407-414.
121. Baglin T Douketis J Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010; 8(11):2436-2442.
122. Iorio A Kearon C Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010; 170(19):1710-1716.
123. Schulman S Wahlander K Lundstrom T Clason SB Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003; 349(18):1713-1721.
124. Schulman S Lindmarker P Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006; 4(4):734-742.
125. Schulman S Svenungsson E Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of anticoagulation study group. Am J Med. 1998; 104(4):332-338.
126. Rodger MA Kahn SR Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008; 179(5):417-426.
127. Palareti G Legnani C Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003; 108(3):313-318.
128. Douketis J Tosetto A Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010; 153(8):523-531.
129. Verhovsek M Douketis JD Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008; 149(7):481-490.
130. Eichinger S Pabinger I Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997; 77(4):624-628.
131. Ho WK Hankey GJ Quinlan DJ Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006; 166(7):729-736.
132. Lindmarker P Schulman S Sten-Linder M Wiman B Egberg N Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost. 1999; 81(5):684-689.
133. Segal JB Brotman DJ Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009; 301(23):2472-2485.
134. Kearon C Julian JA Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 2008; 112(12):4432-4436.
135. Cosmi B Legnani C Cini M Guazzaloca G Palareti G. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost. 2005; 94(5):969-974.
136. Agnelli G Prandoni P Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003; 139(1):19-25.
137. Kearon C Ginsberg JS Anderson DR, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004; 2(5):743-749.
138. Prandoni P Lensing AW Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002; 137(12):955-960.
139. Carrier M Rodger MA Wells PS Righini M Gall GLE. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost. 2011; 9(6):1119-1125.
140. Piovella F Crippa L Barone M, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica. 2002; 87(5):515-522.
141. McRae S Tran H Schulman S Ginsberg J Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006; 368(9533):371-378.
142. Douketis J Tosetto A Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. Br Med J. 2011; 342: d813.
143. Linkins LA Choi PT Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003; 139(11):893-900.
144. Carrier M Le Gal G Wells PS Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010; 152(9):578-589.
145. Schulman S Beyth RJ Kearon C Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008; 133(suppl 6):257S-298S.
146. Lagerstedt CI Olsson CG Fagher BO Oqvist BW Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985; 2(8454):515-518.
147. Agnelli G Prandoni P Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin optimal duration Italian trial investigators. N Engl J Med. 2001; 345(3):165-169.
148. Campbell IA Bentley DP Prescott RJ Routledge PA Shetty HG Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. Br Med J. 2007; 334(7595):674-680.
149. Palareti G Cosmi B Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006; 355(17):1780-1789.
150. Farraj RS. Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med J. 2004; 25(7):848-851.
151. Bruinstroop E Klok FA Van De Ree MA Oosterwijk FL Huisman MV. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost. 2009; 7(4):611-618.
152. Tan M Mos IC Klok FA Huisman MV. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. Br J Haematol. 2011; 153(2):168-178.
153. Prandoni P Prins MH Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med. 2009; 150(9):577-585.
154. Pierson S Pierson D Swallow R Johnson G Jr. Efficacy of graded elastic compression in the lower leg. JAMA. 1983; 249(2):242-243.
155. Musani MH Matta F Yaekoub AY Liang J Hull RD Stein PD. Venous compression for prevention of postthrombotic syndrome: a meta-analysis. Am J Med. 2010; 123(8):735-740.
156. Prandoni P Lensing AW Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 2004; 141(4):249-256.
157. Brandjes DP Buller HR Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997; 349(9054):759-762.
158. Ginsberg JS Hirsh J Julian J, et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med. 2001; 161(17):2105-2109.
159. Aschwanden M Jeanneret C Koller MT Thalhammer C Bucher HC Jaeger KA. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg. 2008; 47(5):1015-1021.
160. Partsch H Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg. 2000; 32(5):861-869.
161. Partsch H Kaulich M Mayer W. Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome. Int Angiol. 2004; 23(3):206-212.
162. Blattler W Partsch H. Leg compression and ambulation is better than bed rest for the treatment of acute deep venous thrombosis. Int Angiol. 2003; 22(4):393-400.
163. Gerlach AT Pickworth KK Seth SK Tanna SB Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy. 2000; 20(7):771-775.